Stock Scorer

Vitaspring Biomedical Co. Ltd. (VSBC)

Vitaspring Biomedical Co. Ltd. reported revenue of 0 USD for the quarter ending 30 April 2026.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 01-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 April 2026 0 —
Gross Profit Q1 '24 · ending 31 January 2024 0 —
Operating Income Q2 '26 · ending 30 April 2026 -75.8K —
Net Income Q2 '26 · ending 30 April 2026 -75.8K —
Cost of Revenue Q1 '24 · ending 31 January 2024 0 -100.0%
Operating Cash Flow Q2 '26 · ending 30 April 2026 6.1K —
Shares Outstanding Q2 '26 · ending 30 April 2026 207M +0.0%
EPS Q2 '26 · ending 30 April 2026 0.00 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20262026-01-31 0-385.4K-415.4K—
20252025-01-31 0-679.9K-774.9K—
20242024-01-31 0-1.1M-1.1M—
20232023-01-31 0-4.2M-4.2M-77.6K
20222022-01-31 5.6M1.1M909.6K-342.6K
20212021-01-31 248.2K425.4K425.4K—
20202020-01-31 15.1K6.9K6.9K—
20192019-01-31 17.2K-22.4K-22.4K—
20182018-01-31 16.2K-6.4K-6.4K—
20172017-01-31 0—-45—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q1 '272026-04-300
Q4 '262026-01-310
Q3 '262025-10-310
Q2 '262025-07-310
Q1 '262025-04-300
Q4 '252025-01-310
Q3 '252024-10-310
Q2 '252024-07-310
Q1 '252024-04-300
Q4 '242024-01-310
Q3 '242023-10-310
Q2 '242023-07-310
Q1 '242023-04-300
Q4 '232023-01-31-1.5M
Q3 '232022-10-310
Q2 '232022-07-310
Q1 '232022-04-301.5M
Q4 '222022-01-313.5M
Q3 '222021-10-31200K
Q2 '222021-07-311.4M

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '242024-01-310
Q3 '242023-10-310
Q2 '242023-07-310
Q1 '242023-04-300
Q4 '232023-01-31-3.9M
Q3 '232022-10-310
Q2 '232022-07-310
Q1 '232022-04-30568K
Q4 '222022-01-311.5M
Q3 '222021-10-3120K
Q2 '222021-07-31341.2K
Q1 '222021-04-30239.8K
Q4 '212021-01-31112.2K
Q3 '212020-10-310
Q2 '212020-07-310
Q1 '212020-04-300
Q3 '202019-10-313.5K
Q2 '202019-07-313.5K
Q1 '202019-04-306.3K
Q4 '192019-01-312.3K

Operating Income Quarterly

PeriodEndingOperating Income
Q1 '272026-04-30-75.8K
Q4 '262026-01-31-81.5K
Q3 '262025-10-31-135.7K
Q2 '262025-07-31-99.1K
Q1 '262025-04-30-69.1K
Q4 '252025-01-31-126.5K
Q3 '252024-10-31-117.9K
Q2 '252024-07-31-218.7K
Q1 '252024-04-30-216.8K
Q4 '242024-01-31-225.4K
Q3 '242023-10-31-235K
Q2 '242023-07-31-353.6K
Q1 '242023-04-30-304.6K
Q4 '232023-01-31-4.2M
Q3 '232022-10-31-183.2K
Q2 '232022-07-31-174.5K
Q1 '232022-04-30343.1K
Q4 '222022-01-311.4M
Q3 '222021-10-31137.5K
Q2 '222021-07-31250.9K

Net Income Quarterly

PeriodEndingNet Income
Q1 '272026-04-30-75.8K
Q4 '262026-01-31-81.5K
Q3 '262025-10-31-142.5K
Q2 '262025-07-31-110.8K
Q1 '262025-04-30-80.5K
Q4 '252025-01-31-143.1K
Q3 '252024-10-31-196.3K
Q2 '252024-07-31-218.7K
Q1 '252024-04-30-216.8K
Q4 '242024-01-31-225.4K
Q3 '242023-10-31-235K
Q2 '242023-07-31-353.6K
Q1 '242023-04-30-304.6K
Q4 '232023-01-31-4.2M
Q3 '232022-10-31-138.3K
Q2 '232022-07-31-144.1K
Q1 '232022-04-30276.7K
Q4 '222022-01-31586.9K
Q3 '222021-10-31748.5K
Q2 '222021-07-31-250.9K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '242024-01-310
Q3 '242023-10-310
Q2 '242023-07-310
Q1 '242023-04-300
Q4 '232023-01-312.4M
Q3 '232022-10-310
Q2 '232022-07-310
Q1 '232022-04-30922K
Q4 '222022-01-312M
Q3 '222021-10-31180K
Q2 '222021-07-311M
Q1 '222021-04-30294K
Q4 '212021-01-31136K
Q3 '212020-10-310
Q2 '212020-07-310
Q1 '212020-04-300
Q4 '202020-01-318.5K
Q3 '202019-10-313.5K
Q2 '202019-07-313.5K
Q1 '202019-04-30904

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q1 '272026-04-306.1K
Q4 '262026-01-31124
Q3 '262025-10-31-839
Q2 '262025-07-31-1.2K
Q1 '262025-04-30-787
Q4 '252025-01-31-1.8K
Q3 '252024-10-31-6.4K
Q2 '252024-07-31-2.4K
Q1 '252024-04-30-4K
Q4 '242024-01-31-2.6K
Q3 '242023-10-31-4.5K
Q2 '242023-07-31188
Q1 '242023-04-30-27.9K
Q4 '232023-01-315.6K
Q3 '232022-10-312.5K
Q2 '232022-07-31-57.6K
Q1 '232022-04-30-28.1K
Q4 '222022-01-31-28K
Q3 '222021-10-31376.8K
Q2 '222021-07-31-977.3K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q1 '272026-04-30207M
Q3 '262025-10-31207M
Q2 '262025-07-31207M
Q1 '262025-04-30207M
Q3 '252024-10-31207M
Q2 '252024-07-31207M
Q1 '252024-04-30207M
Q3 '242023-10-31207M
Q2 '242023-07-31207M
Q1 '242023-04-30207M
Q3 '232022-10-31206.5M
Q2 '232022-07-31206.5M
Q1 '232022-04-30206.5M
Q3 '222021-10-31205.5M
Q2 '222021-07-31205.5M
Q1 '222021-04-30205.4M
Q3 '212020-10-3154.5M
Q2 '212020-07-3152.4M
Q1 '212020-04-3010.9M
Q3 '202019-10-3110.9M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '272026-04-300.00
Q4 '262026-01-310.00
Q3 '262025-10-310.00
Q2 '262025-07-310.00
Q1 '262025-04-300.00
Q4 '252025-01-310.00
Q3 '252024-10-31-0.01
Q2 '252024-07-31-0.01
Q1 '252024-04-30-0.01
Q4 '242024-01-31-0.01
Q3 '242023-10-31-0.02
Q2 '242023-07-31-0.02
Q1 '242023-04-30-0.02
Q4 '232023-01-31-0.02
Q4 '212021-01-310.00
Q3 '212020-10-310.00
Q2 '212020-07-310.00
Q1 '212020-04-300.00
Q4 '202020-01-310.00
Q1 '202019-04-300.00